Preventing pandemic influenza: An update on vaccine development

Infections in Medicine

Volumn 24, Issue 7, 2007, Pages 292-298

  Atmar, Robert L ^a   Keitel, Wendy A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

A (H5N1); Adjuvant; Influenza; Pandemic; Vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

AVIAN INFLUENZA; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; PANDEMIC; REVIEW;

EID: 39649117298     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Murray PR, Baron EJ, Jorgensen JH. Influenza viruses. In: Murray PR, Baron EJ, Jorgensen JH, et al, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press; 2007:1340-1351.
2. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-1385.
3. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18:64-76.
4. Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health. 1997;87:1944-1950.
5. Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis. 2006;12:881-886.
6. Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis. 2006;12:66-72.
7. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev. 2007;20:243-267.
8. Committee for Human Medicinal Products (CHMP). Guideline on Influenza Vaccines Prepared From Viruses With the Potential to Cause a Pandemic and Intended for Use Outside of the Core Dossier Context. EMEA/CHMP/VWP/263499/ 2006. London: European Medicines Agency; January 24, 2007:1-11.
9. US Food and Drug Administration. Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines. Draft guidance. Available at: http://www.fda.gov/cber/gdlns/panfluvac.pdf. Accessed May 20, 2007.
10. Hehme N, Engelmann H, Kunzel W, et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol. 2002;191:203-208.
11. Stephenson I, Nicholson KG, Gluck R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99(H9N2) vaccine in healthy adults: phase I randomised trial. Lancet. 2003;362:1959-1966.
12. Couch RB, Keitel WA, Cate TR. Improvement of inactivated influenza virus vaccines. J Infect Dis. 1997;176(suppl 1):S38-S44.
13. Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119:841-879.
14. The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis. 2005;11:1515-1521.
15. World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. March 2007. Available at: http://www.who.int/csr/disease/ avian_influenza/guidelines/summaryH520070403.pdf. Accessed June 4, 2007.
16. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001;19:1732-1737.
17. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-1351.
18. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657-1664.
19. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97(H5N3) vaccine: a potential priming strategy. J Infect Dis. 2005;191:1210-1215.
20. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006;43:1135-1142.
21. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19:2673-2680.
22. Ennis FA, Mayner RE, Barry DW, et al. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis. 1977;136(suppl):S397-S406.
23. Lin J, Zhang J, Dong X, et al. Safety and imunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368:991-997.
24. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis. 1983;5:737-747.
25. Smith GJ, Naipospos TS, Nguyen TD, et al. Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology. 2006;350:258-268.
26. Kilbourne ED, Smith C, Brett I, et al. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A. 2002;99:10748-10752.
27. Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis. 2006;194:159-167.
28. Lipatov AS, Hoffmann E, Salomon R, et al. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis. 2006;194:1040-1043.